University of Central Florida

STARS
Honors Undergraduate Theses

UCF Theses and Dissertations

2017

The Role of Frabin (FGD4) in Aggressive Prostate Cancer
Alexia M. Bossan
University of Central Florida

Part of the Medical Molecular Biology Commons

Find similar works at: https://stars.library.ucf.edu/honorstheses
University of Central Florida Libraries http://library.ucf.edu
This Open Access is brought to you for free and open access by the UCF Theses and Dissertations at STARS. It has
been accepted for inclusion in Honors Undergraduate Theses by an authorized administrator of STARS. For more
information, please contact STARS@ucf.edu.

Recommended Citation
Bossan, Alexia M., "The Role of Frabin (FGD4) in Aggressive Prostate Cancer" (2017). Honors
Undergraduate Theses. 162.
https://stars.library.ucf.edu/honorstheses/162

THE ROLE OF FRABIN (FGD4) IN AGGRESSIVE PROSTATE CANCER

by

ALEXIA M. BOSSAN

A thesis submitted in partial fulfillment of the requirements
for the Honors in the Major Program in Biomedical Sciences
in the College of Medicine
and in the Burnett Honors College
at the University of Central Florida
Orlando, Florida

Spring Term, 2017

Thesis Chair: Dr. Ratna Chakrabarti

©2017 Bossan

ii

ABSTRACT
A major problem in prostate cancer (PCa) management is the development of drug resistance. It
is known that there are changes in PCa biology upon prolonged treatment with drugs, including
anti-androgen drugs that alter cellular signaling processes leading to the development of
castration resistant PCa. MicroRNAs (miRNAs) are regulatory molecules that modulate gene
expression through inhibition of protein translation and modulate cellular functions. Altered
expression of miRNAs is often noted in drug resistant cancer including PCa. Studies from our
laboratory have identified a number of down-regulated miRNAs in PCa, including miR-l 7-92a
miRNAs. Frabin (FGD4) is a target of the miR-l 7-92a cluster that was found to be up-regulated
in PCa cells. For this paper’s investigation, an FGD4 knockdown approach was used to identify
the effects on cell viability, cell cycle progression, cell migration and drug sensitivity. Two PCa
cells lines, LNCaP-104S (androgen sensitive) and PC-3 (androgen independent), were used for
our studies. MTS assays for both cell lines showed significant reduction in cell viability
following knockdown of FGD4 compared to transfection with control siRNAs. Cell cycle
analysis revealed an arrest in the G2/M phase of the cells that were transfected with FGD4
siRNAs. Cell migration assays revealed a decrease in migration rate of PC-3 cells after
knockdown, which supports the involvement of FGD4 in actin- cytoskeleton rearrangement.
Treatments with anti-mitotic drug Docetaxel (PC-3) or androgen receptor antagonist
bicalutamide/Casodex (LNCaP-104S) showed improved sensitivity of the FGD4 siRNA treated
cells to these drugs. Our results suggest the potential for FGD4 knockdown to be used in
combination

with

currently

used

drugs,

increasing

chemotherapeutics.

iii

the

effectiveness

of

frontline
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I. INTRODUCTION
Prostate cancer is currently the sixth leading cause of cancer associated death and third most
common type of cancer in the United States [1]. According to the National Cancer Institute, 1 in
7 men will be diagnosed at one point in their life, however, early detection methods and
treatment options in recent years have raised the 5-year survival rate for monitored early stage
prostate cancer to 100%. Nonetheless, patients diagnosed with distant stage prostate cancer
remain at a statistically low 5-year survival rate of only 29.3% [1].

Several key events and processes during cancer progression are currently targeted to achieve
control of cancer growth. A major therapeutic target is inhibition of cell proliferation, primarily
through deprivation of androgen, which prostate tumor cells depend on for growth. However,
resistance to androgen deprivation quickly develops, with the tumor cells finding alternative
proliferation pathways [2]. In effect, increasingly more specific targets are being used to develop
more sophisticated treatment options [3]. In all cancers, metastasis is the critical event that
determines patient survival. As a result, proteins that regulate cell motility, extravasation, and
intravasation have been identified as important targets for preventing metastatic disease [3].
Works from our laboratory identified a Rho GEF protein, FGD4, to be associated with
development of resistance to anti-androgen drugs and may prove to be a potential target for
future therapeutic methods.
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1.1 Prostate Cancer

1.1.1 Epidemiology
Prostate cancer is the most common cause of cancer amongst men in the United States, followed
by lung and colorectal cancer [4]. Prostate cancer rarely occurs before the age of 40, and is seen
most commonly in men aged 65-80 [5]. Even though the American Cancer Society predicts
161,300 new cases this year, only 15% of those are expected to be fatal [5]. The discrepancy
between the prevalence of prostate cancer and the incidence of death from the same disease is
due to factors such as early intervention, rarity of metastasis, slow growth rate and patient age
demographics [1, 5]. In many cases, the late age onset and slow growth rate of the cancer allows
other age-related factors to lead to death of the patient before the cancer does. Other
demographics that increase the risk of prostate cancer are race and socioeconomic status. African
Americans are 60% more likely to develop prostate cancer, as well as more likely to die from the
disease than Caucasian, Asian or Hispanic men [6]. In addition, a lower socioeconomic status
increases the risk of developing prostate cancer, most likely due to its association with poor diet,
high stress and inaccessibility to healthcare.

1.1.2 Androgen Receptor
The androgen receptor (AR) signaling pathways play a critical role in the development of the
immature prostate to its adult mature state [7]. Upon binding of androgens (testosterone or
dihydrotestosterone (DHT)) in the cytoplasm, the AR is translocated to the nucleus where it
dimerizes and interacts with co-regulatory molecules to manipulate transcription of a variety of
genes involved in cell growth, cellular functions and cell behavior [2, 7]. The AR is important in
2

normal regulation and function of the prostate gland, and is present at least in base levels in
almost all beginning-stage prostate cancers [7]. For this reason, therapeutic treatments for
prostate cancer have been focused on deprivation of androgen to specifically target androgensensitive tumor cell proliferation and induce apoptosis [8].

Figure 1. Androgen Receptor (AR) Mechanism. Upon binding of dihydrotestosterone (DHT), the AR goes through
a conformational change that leads to the dissociation of heat shock proteins (hsp90 and hsp70). AR-DHT then
translocates into the nucleus where it gets phosphorylated and homo-dimerizes. At this point, it acts as a
transcription factor by recruiting other transcription factors to form a complex that will bind to the androgen
response element and regulate the transcription of androgen responsive genes.
Source: Meehan KL, Sadar MD. Androgens and androgen receptor in prostate and ovarian malignancies. Front
Biosci. 2003 May 1;8:d780-800

1.1.3 Diagnosis and Current Therapies
Prostate Cancer goes through different stages of progression as it develops, with stage I being the
least worrisome and stage IV being the most advanced before the recurrent stage, which
generally indicates some form of resistance to the treatment [9]. When abnormal prostatic
growths are detected in a patient, a biopsy is performed and a Gleason score is assigned based on
the microscopic appearance of the tumor tissue [9]. A Gleason score is composed of two
numbers ranging from 1-5 that grade the tumor based on gland visibility – with the absence of
3

recognizable glands receiving a score of 5. A higher Gleason score means a more aggressive
cancer [9]. In non-aggressive, slow progression prostate tissue with a low Gleason score, “active
surveillance” and regular biopsies is generally the protocol until medical intervention is deemed
necessary [6].

Current treatments for prostate cancer include, but are not limited to, hormone therapy,
prostatectomy, and chemotherapy [10]. Prostatectomy works well for localized early stage
tumors, while metastatic tumors need to be directly targeted through hormone deprivation
therapy. Treatment options are often combined to ensure the complete eradication of the tumor
cells. For example, androgen deprivation therapy often follows prostatectomies to prevent the
development of any new tumor cells and to induce apoptosis [10]. Several research studies in
both humans and mouse models have suggested a relationship between the levels of cytosolic
AR and the odds of progression to resistance to androgen deprivation therapy [7].

1.1.4 Androgen Independence
Androgen-deprivation drugs such as bicalutamide, or Casodex (CDX), an androgen receptor
antagonist, are effective at specifically preventing proliferation of cancer cells because they
target their dependence on androgen, leading to few side effects. However, some populations
eventually become resistant to androgen-deprivation drugs by finding alternative pathways for
growth, making them very difficult to treat [11]. In the case of castration resistant prostate cancer
(CRPC), stronger and more destructive chemotherapeutic drugs that work through mitotic arrest,
such as Docetaxel (DTX), must be used. Investigation into the other pathways that tumor cells
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use to bypass androgen dependence and become castration resistant could lead to discovery of
potential targets within the cell that can be used for development of more effective therapeutic
drugs, with less damaging side effects.

1.2 miRNAs

1.2.1 miRNA Biogenesis
MicroRNAs (miRNAs) are small non-coding RNAs that are generated de novo within the cells.
The function of miRNAs is to regulate expression of proteins through inhibition of translation.
The action of miRNAs as well as that of small interfering RNAs (siRNAs) is referred to as RNA
interference, or RNAi, a mechanism that regulates gene expression [12]. Expression of miRNAs
is found to be altered in a lot of different diseases, including cancers, and while they are still a
relatively new area of research, their manipulation is recognized to be promising as a potential
therapeutic approach due to the fact that they each target an entire group of genes [13-15]. In
order to better understand the effect of miRNAs, it is necessary to understand the role of each of
its targets and the impact of their regulation.

1.2.2 miRNA Mechanism of Action
Following transcription of a gene in the nucleus, often by RNA polymerase II, the primary RNA
transcript is processed by splicing to form a mature mRNA. This mRNA is then exported into the
cytoplasm where ribosomes translate them into polypeptide chains that fold into functional
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proteins [12]. Small RNA molecules such as miRNAs interfere with the translation process by
binding to the mRNAs, leading to their degradation [13, 16].

There are multiple types of RNA interference molecules, including miRNAs and siRNAs.
siRNAs are derived from long double stranded RNA molecules that are either produced in the
cell or delivered into the cell experimentally [12]. Introduction of siRNAs is frequently used in
research to knock down a gene of interest and determine its role in the cell. Similarly, miRNAs
are transported into the cytoplasm as double stranded precursors following transcription and
processing in the nucleus. Once in the cytoplasm, the protein DICER binds the double stranded
precursors of miRNA and cuts them into short double stranded segments. These short segments
then bind the Argonaut protein, which selects one strand that will stay bound to the Argonaut.
This Argonaut-miRNA complex binds to specific mRNAs, guided by the complementary
miRNA sequence, to form RNA-induced silencing complex (RISC), which inhibits translation.
In the case of miRNAs, only some of the sequence pairs with the mRNA, leading to multiple
target effects [17] [12, 13].

1.3 Expression Knockdown by siRNAs

While a single miRNA has numerous targets, siRNAs bind with high specificity to a single target
sequence, and thus down regulate just a single gene [12]. In addition, while they can be found in
certain cell types, siRNAs are generally incorporated into the cell through transfection, as
opposed to miRNAs, which can be manipulated but are natively present within the mammalian
cell. This makes siRNAs a good research tool for investigating the function of a specific protein
6

in vitro. The siRNA mechanism is transient, lasting only about 72 hours before the siRNAs begin
to degrade and lose their effect in the cell. During this time, experiments can be run with the cells
to determine the effect of the absence of this protein, giving insight into its role in the cell. For
this reason, siRNAs were used as a tool in the investigation of the role of FGD4.

1.4 Rho GTPases

1.4.1 Rho GEFs
The RhoGEFs, or Rho guanine nucleotide exchange factors, are a family of proteins with the
ability to catalyze the exchange of GDP for GTP on small GTPase proteins [18]. GTPases are
molecular switches that control intracellular signaling pathways, regulating cell movement and
proliferation [18]. When bound to GTP, GTPases are active and trigger activation of signaling
proteins. The most widely studied families of GTPases are Cdc42, Rac1 and RhoA. Regarding
their effect on the actin filament, Cdc42 induces filopodium formation, Rac1 induces formation
of lamellipodia or ruffles, and RhoA regulates the assembly of stress fibers and focal adhesion
complexes [19, 20].

GEFs are a diverse group of proteins. Some GEFs are highly specific for a single GTP binding
domain, while others have multiple substrates. One family of GEFs are FGD proteins, “FYVE,
RhoGEF and PH domain containing” proteins, which regulate Rho A and CDC42 [21]. Frabin
(FGD4) belongs to this family. While relatively little is known about this protein, published
studies found that FGD4 plays a role in coupling the actin cytoskeleton with the plasma
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membrane, together with other Cdc42 GEFs such as FGD1, FGD2, and FGD3 [22-24]. FGD4 is
unique in the FGD family for having a functional actin-binding domain and was originally
identified as an actin-binding protein [22] [23] [25]. It seems that FGD4 associates with an actin
structure in a way that activates Cdc42 and leads to reorganization of the actin cytoskeleton [22,
23, 26].

1.4.2 FGD4 involvement in disease
It is known from published literature that the FGD4 gene is involved in a genetically inherited
neuromuscular disease called Charcot-Marie-Tooth (CMT) disease, but its role has only recently
been investigated in relation to prostate cancer [27]. Mutations of the FGD4 gene have been
shown to cause abnormalities in the myelin sheath of Schwann cells in the peripheral nervous
system, which is regulated by Cdc42 [27].

1.4.3 FGD4 regulation by miRNA cluster miR-17-92a
Previous studies from our laboratory have identified a miRNA cluster miR17-92a to be down
regulated in prostate cancer [28, 29]. Stable expression of this cluster in PC-3 cells resulted in
decreased expression in FGD4, LIMK1, SSH1 and cyclin D, all of which had been predicted to
be target sequences of miRNAs miR-17 and -20a [29]. Experimental evidence confirmed the
regulation of FGD4, an activator of the Rho GTPase pathway, by miRNAs miR-17 and -20a
from the miR17-92a cluster [29]. This is further supported by microarray analysis showing
FGD4 to be elevated in aggressive prostate tumor tissues, in line with its regulatory miRNA
cluster being down regulated in aggressive tissues (unpublished data). Thus, in normal cell lines,
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miRNAs miR-17 and -20a suppress the expression of FGD4 to minimal levels, which explains
why prostatic tissue expresses elevated levels of FGD4 if expression of the miR-17-92a cluster is
low.

The aim of this study is to determine the role of FGD4 in prostate cancer and whether it could
potentially be used in synergism with existing drugs as a therapeutic target.
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II. MATERIALS AND METHODS
2.1 Research Objectives and Design

The role of FGD4 was investigated through a set of functional studies to monitor proliferation,
cell cycle progression, cell migration, and drug sensitivity after knockdown of FGD4. Two cell
lines representing different stages of PCa progression, LNCaP-104S (androgen dependent) and
PC-3 (advanced androgen-independent), were used in transient knockdown experiments. The cell
lines were transfected with FGD4 siRNAs to determine the effect of protein knockdown on
aspects of cell behavior compared to controls. qRT-PCR analysis of FGD4 mRNA levels was
used to confirm the reduced expression of FGD4 mRNA following transfection with siRNAs.
Henceforth, experiments were carried out to demonstrate the effect of FGD4 down-regulation on
the following:


Proliferation
a. Viability: using MTS assays to determine the number of live cells.
b. Cell cycle: using PI staining and flow cytometry analysis to visualize G1, S,
G2/M phases.



Behavior
a. Migration: using scratch assays to compare distance traveled over a time interval
compared to controls.
b. Activation of Cdc42: using a G-LISA Cdc42 Activation assay to determine if this
pathway is disrupted by the knockdown of FGD4



Sensitivity to Drugs
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a. Drug Treatments: using an MTS assay to visualize cytotoxic effects of CDX and
DTX on LNCaP-104S and PC-3, respectively.

2.2 Cell Culture
Cell lines were maintained in 60 cm2 culture dishes at 37oC with 5% CO2. LNCaP104-S cells
were maintained in DMEM with 10% heat-inactivated fetal bovine serum (HI-FBS), 1%
Antibiotics and Anti-mycotics (A/A) and 1nM dihydrotestosterone (DHT). PC-3 cells were
maintained in F12-K medium with 10% HI-FBS and 1% A/A. Media were replaced 2-3 times a
week for PC-3 and sub-cultured every 2-3 days in tissue culture dishes with a 60 cm2 surface
area; 3-4 days for LNCaP-104S. 2-3 mL of 1X Trypsin-EDTA was used to detach the cells from
the dish in order to subculture, as per ATCC culture guidelines (ATCC).

Table 1. Number of cells seeded per well prior to transfection.

LNCaP-104S

PC-3

96-well

6,000

3,000

24-well

60,000

30,000

12-well

100,000

60,000

6-well

180,000

150,000

2. 3 Transfection

The cells were seeded 24 hours prior to transfection, for ~70% confluency at the time of
transfection. The volumes dispensed were as indicated in the table below. For each siRNA, the
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indicated amount of siRNA was combined with the indicated volume of opti-MEM in a tube, and
another tube was used to dilute the indicated volume of RNAiMax in the same amount of
optiMEM. For multi-well transfections, a master mix was prepared for the RNAiMax dilution
mix. Both tubes were vortexed to ensure homogeneity. The appropriate amount of master mix
was added to the siRNA tube and the mixture was vortexed for 5 seconds. The mix was left to
incubate for 10 minutes at room temperature. The mixture was then added to the cells, making
sure to spread the volume over the entire surface area of the dish as well as carefully mixing by
moving the plate in concentric circles. The cells were placed in the incubator at 37oC and the
media were changed after 8 hours. The cells were incubated at 37oC for a total of 48 hours after
transfection.

Table 2: Volumes per well for siRNA Transfection

Dish

FGD4 siRNA volume

RNAiMax

Opti-MEM volume/ mix

6-well

2.3 l

9 l

150 l

12-well

1.5 l

6 l

100 l

24-well

1.0 l

2.3 l

37.5 l

96-well

0.25 l

0.31 l

9.4 l
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2.4 RNA extraction and qRT-PCR

qRT-PCR was performed to confirm the effect of siRNAs on the FGD4 mRNA levels. RNA was
extracted from the cells 48 hours after transfection in a 12-well plate. QIAGEN RNeasy kit was
used for the RNA extraction according to the manufacture’s protocol, using precautions to avoid
RNA degradation and contamination. RNA samples were stored at -80oC until needed. The
concentration of the extracted RNA was determined using the Nanodrop spectrophotometer.
QuantiTect Reverse Transcription Kit was used for the synthesis of cDNA. 2 µL of 7xgDNA
Wipeout Buffer and 500ng of the template RNA were diluted to a total reaction volume of 14 µL
with RNase-free water and incubated for 2 minutes at 42 oC, and then immediately placed on ice.
The reverse-transcription (RT) master mix was prepared, except the template RNA, and kept on
ice. The master mix included 1 µL of Quantiscript Reverse Transcriptase, 4 µL of 5x
Quantiscript RT Buffer, 1 µL of RT primer Mix. The RNA template mix was added to each tube
of master mix and then placed on ice. Once all of the samples were ready, the tubes were
incubated at 42oC for 15 minutes, then incubated for 3 minutes at 95oC to inactivate the
Transcriptase enzyme. The tubes were then placed on ice until ready for real-time qPCR. A 10
µL reaction volume was used for the qPCR reaction: 5 µL of 2x Rotor-Gene SYBR Green PCR
master mix, 1 µL of 10x QIAGEN FGD4 Quantitect Primer (Qiagen: Cat. No. QT00019628)
mix and 2 µL of 1:5 dilution of cDNA were mixed and 2 µL of RNase-free water was added to
amount to 10 µL total. Reactions were run on a Qiagen Rotor-Gene Q qPCR machine for 40
cycles and data were analyzed using the 2-ΔΔCT Livak-method (Livak et al., 2001) to express
relative expression changes. RPL13a (Qiagen: Cat. No. QT00089915) and Eif3d (Qiagen: Cat.
No. QT00010829) were used as normalizer genes.
13

2.5 Western Blot Analysis of Protein Expression

2.5.1 Cell Lysate Preparation
A Western Blot was used for analysis of the cell lysates for FGD4 protein expression following
transfection to determine the effect of siRNAs at the protein level. 48 hours after transfection, the
cells were trypsinized and pelleted and a volume proportional to the size of the pellet of cold
RIPA lysis buffer with protease and phosphatase inhibitor was used to re-suspend the pellet. The
pellet was then flash-frozen in a dry-ice ethanol bath and thawed immediately in a 37oC. The
lysates were then spun at maximum speed in a 4oC micro centrifuge and then checked under a
microscope slide to ensure complete lysis of the cells. The lysates were transferred to new tubes.

2.5.2 Protein Quantification
A Bradford assay was used to quantify the protein concentration in each sample and used to
determine the amount of lysate needed to equalize the samples for loading into the gel. 1 mL of
20% Bradford dye in dH2O was added to each cuvette and along with 1 µL of lysate. This was
done in duplicate for each sample. The absorbance was read at 595nm on a spectrophotometer
and an absorbance of 0.2 – 0.5 was considered accurate. If the sample absorbance was out of
range, the samples were either diluted or in the case of it being too dilute, 2 µL of lysate was
added instead and the concentration was adjusted accordingly. The volume of lysate needed to
load 50 µg of protein lysate per well up to a total volume of 16 µL per sample. 4 µL of 5X
Laemmli loading buffer was added to bring the total volume to 20 µL per sample.
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2.5.3 SDS-PAGE and Western Blotting
An SDS-PAGE gel was run to separate the complete cell lysate by size in order to visually
isolate the 105 kDa band pertaining to human FGD4. Molecular weight markers and equal
amounts of protein were added to the wells of a 10% SDS Page gel. The gel was run at 50V for 5
minutes before being increased to 80V and allowed to run until the dye front ran off the gel,
approximately 3 hours. The gel was then placed in 1x transfer buffer for 15 minutes. The transfer
sandwich was then assembled tightly into an XCell II™ Blot Module with the blot on the
cathode and the gel on the anode. The cassette was placed in the transfer tank and set to transfer
overnight at 4oC at 20V. Once transferred, the membrane was rinsed with Tris-buffered saline
with 0.05% Tween-20 (TBS-T), after which it was stained with India ink for 15 minutes. It was
then blocked for 2.5 hours in 20 mL of milk-TBS-T (5% non-fat milk dissolved in TBS-T). A
surf blotter was placed on top of the membrane, making sure each lane was matched to a
channel. 160 µL of FGD4 antibody (GeneTex FGD4 antibody [N1N3] 1:350) dilution in milkTBS-T was added to each lane and placed on a rocker overnight at 4oC. The following day, the
surface blotter was removed and the membrane was washed for 2 minutes with TBS-T and then
3 times for 7 minutes with 5% milk-TBS-T. 5% milk was decanted and 40 mL of fresh milkTBS-T containing the secondary antibody (goat anti-rabbit HRP, 1:5000) was added to the
membrane and the container was set to rock for 45 minutes. Another wash with TBS-T was
repeated 3 times for 15 minutes each time, after which the TBS-T was replaced with fresh TBST and brought to the Gel Doc for imaging. 1 mL of enhanced chemiluminescence (ECL) solution
was pipetted evenly over the surface of the membrane. This reaction was allowed to sit and
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proceed for ~3 minutes. A Gel Doc was used to image the membrane over the course of a ~3minute exposure period.

2.6 MTS Assay and Drug Treatments

24 hours prior to transfection, 6.000 cells (PC-3) or 10.000 cells (LNCaP-104S) were seeded per
well of a 96-well plate, in a volume of 100 µL per well. 24 (PC-3) or 48 (LNCaP-104S) hours
later, the cells were transfected. The transfection media were changed after 8 hours and replaced
with fresh media. For drug treatment trials, the media were replaced with 10 µM Casodex in
20% charcoal-stripped FBS (CS-FBS) growth medium (LNCaP-104S) or 5nM and 25nM
Docetaxel in regular complete growth medium (PC-3). MTS tetrazolium salt reagent in powder
form (Promega) and phenazine methasulfate (PMS) were used to prepare the MTS/PMS reagent
according to the CellTiter® AQueous Non-Radioactive Cell Proliferation Assay from Promega. 20
µL of the prepared MTS/PMS solution was added to each of the wells and culture plates were
incubated at 37oC for 3 hours. Metabolic enzymes in viable cells convert MTS into formazan, a
compound that is soluble in cell media. The amount of formazan product formed can be
measured by the absorbance at 490 nm and is proportional to the number of living cells in a well.

2.7 PI staining and Cell Cycle Analysis

60,000 cells were seeded in a 12-well plate and transfected 24 hours later. The media were
replaced after 8 hours. 48 hours after transfection, the cells were detached from the wells with
10X trypsin-EDTA, spun down at 1300 rpm and rinsed twice with PBS. The cells were spun
16

down again and re-suspended in 300 µL of cold PBS before being placed on ice. 800 µL of icecold methanol was added to the cells while vortexing at low speed to fix and permeabilize the
cells. The cells were left at -20 degrees in methanol for 30 minutes. The tubes were returned to
ice and 10 mL of cold PBS was added to the tubes, which sat on ice for 5 minutes to rehydrate
the cells before spinning down. The cells were centrifuged and rinsed with PBS twice before
spinning down again and re-suspending with 100 µL of 50 µg/mL RNase/2% Bovine Serum
Albumin (BSA) in PBS. The tubes were incubated for 15 minutes at room temperature and then
transferred to round-bottom polystyrene tubes using 400 µL of 2% BSA in PBS. 100 µL of 200
µg/mL propidium iodide (PI) in 2% BSA in PBS solution were added to each tube and the tubes
were incubated in the dark at room temperature for 1 hour. The cells were run in a BD Accuri
flow cytometer until a count of 10,000 PI-stained events was obtained per sample. FlowJo
Analysis software was used for cell cycle analysis.

2.8 Migration Assay

40,000 cells were seeded into a 24-well plate, 24 hours prior to transfection of FGD4 siRNAs.
After transfection, cells were incubated for 8 hours at 37 degrees before the wells were replaced
with fresh medium. Incubation of cells were continued for a total of 48 hours after transfection.
Using a 1 mL pipette tip, a cross was scratched out of the cell sheet on the plate and the detached
cells were washed off with PBS. Photos were taken of the cells as time point 0. The cells were
placed back in the incubator at 37oC with fresh media and the media was replaced again after 14
hours before taking pictures of the second time point. A small surgical blade was used to carve
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small lines in the plastic under each well to mark and keep track of the positions at which the
pictures were taken.

2.9 Cdc42 Activation Assay

2.9.1 Lysate Preparation
Cells were plated and grown in 4 wells of a 12-well dish to a 70% confluency and transfected
with FGD4 siRNA #6 and control siRNA (2 of each). At the time of collection, the dish was
immediately placed on ice, media was aspirated, and cells were washed with ice-cold phosphate
buffered saline (PBS) to remove remaining serum proteins. The PBS was completely aspirated to
assure the lysis buffer was not diluted. The lysis buffer was provided with the kit; 120 µL of cold
lysis buffer was used per well of cells. The lysates were collected for each sample, mixed with a
cold pipette tip, and 20 µL of each sample was placed in a duplicate tube, which was placed on
ice. The tubes containing the remaining 100 µL of lysate were snap-frozen using liquid nitrogen
and stored at -80oC until the assay could be run. The tubes containing 20 µL of sample were
stored on ice and used to quantify the protein concentration using the provided reagent to read it
on the spectrophotometer.

2.9.2 G-LISA Assay
The lysates were thawed in a room temperature water bath and then immediately placed on ice.
The samples were prepped by standardizing them with lysis buffer if they were of different
concentrations. Cdc42-GTP strips provided with the kit were placed on the provided rack and
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sterile water was added to the well of the strip to dissolve the Cdc42-GTP-binding protein
powder found in the wells. The water was removed by flicking the plate rigorously. 50 µL of
each sample was added to the wells and the entire 96-well rack was placed on a cold orbital
shaker set to 400 rpm for 15 minutes. Wash buffer provided with the kit was used to wash the
wells after each step of the protocol, removing each time by rigorously flicking the plate. After
two washes to remove the samples from the wells, 200 µL of Antigen Presenting Buffer was
added to each well and incubated for 2 minutes at room temperature. The wells were then
washed again three times. In a new tube, a dilution of 1/20 of primary antibody was made in
antibody dilution buffer and placed on ice. The same was done with the secondary antibody but a
1/62.5 dilution was made instead. 50 µL of anti-Cdc42 antibody were added to the wells and
placed on the room temperature orbital shaker at 400 rpm for 30 minutes. The wells were then
washed three times and 50 µL of the secondary antibody dilution were added to the wells, and
then incubated for another 30 minutes at room temperature on the orbital shaker at 400 rpm. The
wells were washed again 3 times and then 70 µL of HRP detection reagent mix was added. The
plate was placed at 37oC and allowed to incubate for 15 minutes before the addition of 140 µL of
HRP stop buffer and the reading at 490 nm.
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III. RESULTS
3.1 FGD4 levels vary among cell lines

qRT-PCR was used to analyze the mRNA levels in various cell lines: three prostate cancer lines
from varying stages of aggression and one unrelated, leukemia cell line. In contrast to
preliminary studies that found that prostate tissue samples indicated increased levels of FGD4
with increased characteristic aggression level, the most aggressive PCa cell line, PC-3, actually
showed very low levels of FGD4 mRNA expression (Figure 2). LNCaP-104S and 22Rv1
showed similar levels, both about 15x greater than expression levels in the non-prostatic
leukemia line, K562. In order to determine the role of FGD4 across a variety of cells, one
androgen sensitive cell line expressing high FGD4 mRNA levels, LNCaP-104S, and one
androgen insensitive cell lines expressing lower levels, were used in knockdown experiments.
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Figure 2: Relative levels of FGD4 mRNA in various cell lines. Total RNA was extracted from the whole cell
lysates of various cell lines and qRT-PCR was used to compare baseline expression levels of FGD4 mRNA. K562 is
a non-prostatic leukemia cell line. PC-3 is a bone metastatic PCa cell line with a mutated androgen receptor
(androgen insensitive). LNCaP-104S is an androgen sensitive PCa cell line isolated from the lymph node. 22Rv1 is a
prostate cancer xenograft-derived cell line.
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3.2 FGD4 siRNAs led to 70% decrease in FGD4 mRNA expression

To determine the efficacy of the siRNA mediated knock-down of FGD4, we conducted qRTPCR analysis comparing RNA extracted from FGD4 siRNA transfected PC-3 cells to that from
controls. Results confirmed significant reduction of FGD4 mRNA of 60-80%, confirming
intended effect of siRNAs. FGD4 siRNA #6 resulted in the most effective knockdown of the
target mRNA compared to the others, with approximately 80% reduction every time (Figure 3).
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Figure 3: FGD4 siRNAs reduced FGD4 mRNA concentration. qRT-PCR analysis was run using RNA extracted
from the transfected cells and data revealed at least 70% reduction in FGD4 mRNA by FGD4 siRNAs compared to
controls. (Welch’s t-test p-value * < 0.001).
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3.3 FGD4 siRNAs led to a 70-80% decrease in FGD4 protein expression

After showing that there was a significant effect of the siRNAs on FGD4 mRNA, a western blot
was used to determine the effect on FGD4 protein expression (Figure 4). Western blot analysis
and quantification revealed a significant average of 60-80% knockdown of the FGD4 protein
expression.
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Figure 4: Western Blots showed reduction in FGD4 protein expression by FGD4 siRNAs in LNCaP-104S (A)
and PC-3 cells (B). Left panel: Total protein extracts were used for the detection of FGD4 expression using antiFGD4 antibodies (1:350 dilution). Right panel: Densitometry analysis of FGD4 expression using GAPDH and tubulin as the loading controls.
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3.4 Knockdown of FGD4 reduced cell viability
Viability assays were performed to determine if the cell’s viability or proliferation is
compromised in any way by the knockdown of FGD4. Four FGD4 siRNAs were used in this
assay to eliminate potential off-target effects. All four siRNAs were confirmed to result in at
least 70% reduction of FGD4 mRNA in both cell lines through qRT-PCR analysis. MTS assays
showed a significant 10-23% decrease in cell viability of PC-3 cells when transfected with FGD4
siRNAs and compared to control siRNAs (Figure 5A). Knockdown of FGD4 in LNCaP-104S
cells also showed a significant effect, though it was slightly less than the effect on PC-3 cells,
with 8-13% reduction in viability compared to controls (Figure 5B). FGD4 siRNAs #2 and #6
showed the strongest effect on cell viability and were therefore chosen to be used in further
experiments.
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Student’s t-test * p-value < 0.05, ** p-value < 0.005
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Figure 5: FGD4 siRNA reduced cell viability. MTS assay performed with PC-3 cells (A) and LNCaP-104S cells (B). Cells were seeded to a 70% confluency in
a 96-well plate and transfected using 4 different FGD4 siRNAs and 3 control siRNAs. Each transfection was performed in triplicate and each experiment was
repeated at least 3 times. At 48 hours after transfection, MTS reagent was added to the wells, incubated for 3 hours and the absorbance at 490 was measured in a
spectrophotometer. FGD4 siRNAs showed a significant decrease in viability compared to control siRNAs. (Welch’s t-test p-value * < 0.05, ** < 0.005, **** <
0.0001).
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3.5 Knockdown of FGD4 resulted in G2/M arrest

As we determined that FGD4 knockdown reduces cell viability, we analyzed the effect of FGD4
knockdown on cell cycle progression using PI staining and flow cytometry. In both cell lines,
knockdown of FDG4 resulted in G2/M arrest during the cell cycle (Figure 6 and Figure 7). Cell
cycle analysis of FGD4 siRNA transfected cells confirmed a 20-40% increase in the G2/M phase
and a decrease in number of cells in G1 phase compared to control siRNAs (Figure 6 and
Figure 7).
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Figure 6: FGD4 knockdown arrested cells in G2/M phase of PC-3. (A) The effect of FGD4 knockdown on phases
of the cell cycle in PC-3 cells. (B and C) Two parameter histogram showing a higher G2/M peak in siRNA
transfected cells (C) compared to control RNA transfected cells (B). (Welch’s t-test p-value * < 0.05 *** < 0.001).
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Figure 7: FGD4 knockdown arrested cells in G2/M phase of LNCaP-104S. (A) shows graph of FGD4 knockdown
effect on phases of the cell cycle in LNCaP-104S cells. siRNA transfected cells resulted in histogram with higher
G2/M peak and lower G0/G1 peak (C) compared to control siRNA (B). (Welch’s t-test p-value * < 0.05 ** < 0.01,
*** < 0.001).
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3.6 Inhibition of FGD4 expression reduced cell migration

FGD4 is noted to be an actin-cytoskeleton rearrangement protein (ref). To assess the role of
FDG4 on cell migration, we performed scratch assays and show that inhibition of FGD4
expression through siRNA transfection results in a significant decrease in the migratory rates of
PC-3 cells compared to control siRNAs. Scratch assays revealed nearly a 40% decrease in the
rate of migration of cells upon knockdown of FGD4 compared to controls (Figure 8),
confirming the involvement of FGD4 in facilitating cell migration rate and contributing to the
high metastatic phenotype of PC-3, perhaps through the suggested involvement in regulation of
actin-cytoskeleton

rearrangement.………………………………………………………………..
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Figure 8: FGD4 knockdown decreased migration rate of PC-3 cells. PC-3 cells were seeded in a 24 well plate to a confluency of 80%. After 24 hours, the cells
were transfected with siRNAs. A scratch was made 48 hours after transfection using a micropipette tip and photos were taken at t = 0 and t = 14 hours (A). The
cells transfected with FGD4 siRNAs showed a significantly (Welch’s t-test p-value **** < 0.0001, when compared to CLT1) decreased migration rate compared
to control siRNAs (B).
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3.7 FGD4 knockdown reduced Cdc42 activation

Upon observation of the effect of FGD4 knockdown on migration rate, a Cdc42 activation assay
was run on cells transfected with FGD4 siRNA #6 or control siRNA to determine if the Cdc42
activation is decreased upon reduction of FGD4. Cells transfected with the FGD4 siRNA showed
approximately 30% reduction of Cdc42 activation compared to control siRNA (Figure 9),
confirming the involvement of FGD4 in Cdc42 activation.
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Figure 9. Knockdown of FGD4 decreased Cdc42 Activation. G-LISA Cdc42 Activation Assay Kit was used on
PC-3 cells transfected with FGD4 siRNA #6. Bar graph showing approximately 30% decrease in Cdc42 activation
in FGD4 siRNA #6 vs. Control siRNA (Welch’s t-test p-value ** < 0.01).
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3.8 Knockdown of FGD4 improved drug sensitivity

Based on the MTS assay results that showed siRNAs #2 and #6 to have the most effect on cell
viability, these two were chosen for drug sensitivity assays with the suspicion that they could
make the cells more susceptible to drug treatment. The siRNAs were tested in combination with
currently used prostate cancer drugs to determine if FGD4 knockdown could increase drug
sensitivity. LNCaP-104S cells, being an androgen sensitive cell line, was treated with 10uM
CDX (AR antagonist) after transfection with FGD4 siRNAs. Compared to siRNA controls, the
FGD4 knockdown resulted in a 10-15% increase in sensitivity to the drug, with a similar
different for DMSO vehicle control (Figure 10). Since PC-3 cells have a mutated androgen
receptor, they are androgen independent and insensitive and do not respond to androgen
antagonists. In this case, Docetaxel, which exerts its toxic effects through mitotic arrest, was
used in 5nM and 25nM concentrations to see if FGD4 knockdown might work synergistically
with Docetaxel treatment and increase the cell’s sensitivity to the drug. Indeed, MTS assays
indicated an 8-15% increase in sensitivity to Docetaxel than to ethanol vehicle control (Figure
10).
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IV. DISCUSSION

4.1 The role of FGD4 in metastasis

The results of migration studies using FGD4 siRNAs strongly support previous reports of FGD4
expression influencing migratory behavior and its involvement in actin cytoskeleton
rearrangement. GST pull-down assays have shown FGD4 to be the middle protein in a cascade
ultimately leading to activation of the Cdc42 pathway in nasopharyngeal carcinoma (NPC) cells
[30]. The Cdc42 pathway triggers rearrangement of the actin cytoskeleton characteristic of
malignant tumor cells for increased migratory behavior. FGD4 has been confirmed as a target of
the miRNA cluster miR17-92a, which is differentially expressed in many cancers including
prostate, oral, breast, skin and cervical cancer [29] [3] [31].

Yang et al. show one of the miRNAs from the cluster that was identified to regulate FGD4, miR17, to slow down tissue growth, decrease cell adhesion and decrease migration rate, further
supporting our results [32]. While they identified other targets of this miRNA as being associated
with this altered behavior, miRNAs are known to have multiple targets and the synergistic effect
of all of them acting at the same time may be the reason for such complex disease states.
Contradictory findings in cervical cancer cells state that upregulation of miR-20a, the other
miRNA that was shown to target FGD4, is responsible for an increase in cell proliferation and
migration [31]. It would be interesting to investigate whether FGD4 is upregulated or down
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regulated in these cancer cells, and whether it is the role of FGD4 that changes or the fact that
miR-20a regulates it in opposing ways in different cellular environments.

It is clear that expression of FGD4 is involved in the regulation of metastatic behaviors such as
cell migration and increased proliferation in prostate cancer, among others. It is also evident,
from research contradicting such findings at the miRNA level, that different cancers and cell
types show varying degrees of dependence of particular gene expression, possibly only at the
miRNA level, but also possibly at the functional level of proteins.

4.2 FGD4 as a potential therapeutic target for aggressive prostate cancer

Insight into pathways that play a role in tumorigenesis can lead to treatments specific to cancer
cells that cause less harm to other cells in the body. Results of this study have confirmed a
significant involvement of FGD4 in the tumorigenic behaviors exhibited by aggressive prostate
cancer cell lines, but not to the exclusion of multiple other pathways involved in the same
mechanisms. Cell cycle analysis revealed an arrest in the G2/M phase that could suggest cells are
being halted at the G2/M checkpoint. Involvement of FGD4 in the checkpoint to proceed with
mitosis may be related to the finding that knockdown of FGD4 led to an increase in sensitivity to
docetaxel, which targets mitotic spindle formation. Further elucidation into the branches of such
pathways can enhance the benefits of specific targeting as a therapeutic aid.

Despite other factors being involved in cell cycle regulation and migration, FGD4 siRNAs led to
almost a 50% reduction in migration rate, which suggests the therapeutic potential of FGD4
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knockdown to slow cancer progression and change the migratory phenotype of PCa cells. A
significant decrease in Cdc42 activation resulted from FGD4 knockdown, as well as a significant
decrease in migration and invasive behavior, suggesting a possible mechanism for decreased
migration rate. While no current available treatments for prostate cancer target the Cdc42
pathway or related Rho-GEFs and –GTPases, small molecule inhibitor AZA197 targeting Cdc42
has been shown to reduce tumor sizes of colorectal cancer in mice [33].

4.3 Future studies

Further investigation into the role of proteins such as FGD4, as well as elucidation of the
pathways surrounding it and its regulators, has potential for research in the area of therapeutic
advancement. To support the functional data obtained after FGD4 suppression, overexpression
studies will be performed. If overexpression studies support the knockdown data in 2D models,
further investigation should aim to confirm the findings in more physiologically replicable
models. 3D tissue culture should follow, with design of a method to monitor morphological
changes of the cells in response to FGD4 knockdown. Direct injection of an FGD4 deficient or
overexpressing cell line into a mouse model and monitoring tumor progression compared to the
control cell line would allow for physiologically relevant data. Mouse models would be the ideal
method of truly investigating the suggested synergistic effect of FGD4 knockdown on sensitivity
to docetaxel and bicalutamide (Casodex).

Evidently, FGD4 plays a role in migration of aggressive cell lines, even when it is not present in
significant amounts, as seen by knockdown assays using PC-3. Much potential stems from the
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identification of a metastatic player in prostate cancer: interaction studies involving other
proteins known to be associated with FGD4 in other cancers, such as LMP1 seen in
nasopharyngeal carcinoma, may elucidate pathway interactions and common activators that
could make even better therapeutic targets down the line [30].

40

REFERENCES

1.

NIH. Cancer of the Prostate - Cancer Stat Facts. 2017; Available from:
https://seer.cancer.gov/statfacts/html/prost.html.

2.

Javidan, J., et al., The androgen receptor and mechanisms for androgen independence in
prostate cancer. Cancer Invest, 2005. 23(6): p. 520-8.

3.

Brown, B.D., et al., Endogenous microRNA can be broadly exploited to regulate
transgene expression according to tissue, lineage and differentiation state. Nat
Biotechnol, 2007. 25(12): p. 1457-67.

4.

Prevention, C.f.D.C.a., CDC - Cancer Statistics - Men. 2017.

5.

Society, A.C., Key Statistics for Prostate Cancer. 2017.

6.

America, C.T.C.o., Prostate Cancer Diagnosis, Treatments & Therapies | CTCA. 2017.

7.

Lonergan, P.E. and D.J. Tindall, Androgen receptor signaling in prostate cancer
development and progression. J Carcinog, 2011. 10: p. 20.

8.

Cucchiara, V., et al., Epigenomic Regulation of Androgen Receptor Signaling: Potential
Role in Prostate Cancer Therapy. Cancers (Basel), 2017. 9(1).

9.

America, C.T.C.o., Prostate Cancer Stages: What are the Stages? | CTCA. 2017.

10.

Mayo Clinic., Prostate cancer Treatments and drugs - Mayo Clinic. 2017.

11.

Seruga, B., A. Ocana, and I.F. Tannock, Drug resistance in metastatic castrationresistant prostate cancer. Nat Rev Clin Oncol, 2011. 8(1): p. 12-23.

12.

Mack, G.S., MicroRNA gets down to business. Nature Biotechnology, 2007. 25(6): p.
631-638.

41

13.

Bartel, D.P., MicroRNAs: target recognition and regulatory functions. Cell, 2009.
136(2): p. 215-33.

14.

Oliveto, S., et al., Role of microRNAs in translation regulation and cancer. World J Biol
Chem, 2017. 8(1): p. 45-56.

15.

Ramamurthy, V.P., et al., Targeting of protein translation as a new treatment paradigm
for prostate cancer. Curr Opin Oncol, 2017.

16.

Stefani, G., Roles of microRNAs and their targets in cancer. Expert Opin Biol Ther,
2007. 7(12): p. 1833-40.

17.

Lim, L.P., et al., Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature, 2005. 433(7027): p. 769-773.

18.

Spiering, D. and L. Hodgson, Dynamics of the Rho-family small GTPases in actin
regulation and motility. Cell Adh Migr, 2011. 5(2): p. 170-80.

19.

Miller, N.L., E.G. Kleinschmidt, and D.D. Schlaepfer, RhoGEFs in cell motility: novel
links between Rgnef and focal adhesion kinase. Curr Mol Med, 2014. 14(2): p. 221-34.

20.

Vega, F.M., et al., The Rho GTPase RhoB regulates cadherin expression and epithelial
cell-cell interaction. Cell Commun Signal, 2015. 13: p. 6.

21.

Minami, K., et al., miRNA expression atlas in male rat. Sci Data, 2014. 1: p. 140005.

22.

Obaishi, H., et al., Frabin, a novel FGD1-related actin filament-binding protein capable
of changing cell shape and activating c-Jun N-terminal kinase. J Biol Chem, 1998.
273(30): p. 18697-700.

23.

Ono, Y., et al., Two actions of frabin: direct activation of Cdc42 and indirect activation
of Rac. Oncogene, 2000. 19(27): p. 3050-8.

42

24.

Ayala, I., et al., Faciogenital Dysplasia Protein Fgd1 Regulates Invadopodia Biogenesis
and Extracellular Matrix Degradation and Is Up-regulated in Prostate and Breast
Cancer. 2009.

25.

Ikeda, W., et al., Cooperation of Cdc42 small G protein-activating and actin filamentbinding activities of frabin in microspike formation. Oncogene, 2001. 20(27): p. 3457-63.

26.

Nakanishi, H. and Y. Takai, Frabin and other related Cdc42-specific guanine nucleotide
exchange factors couple the actin cytoskeleton with the plasma membrane. J Cell Mol
Med, 2008. 12(4): p. 1169-76.

27.

Stendel, C., et al., Peripheral nerve demyelination caused by a mutant Rho GTPase
guanine nucleotide exchange factor, frabin/FGD4. Am J Hum Genet, 2007. 81(1): p.
158-64.

28.

Ottman, R., Nguyen C., Lorch R., Chakrabarti R. , MicroRNA expressions associated
with progression of prostate cancer cells to antiandrogen therapy resistance. Molecular
Cancer, 2014. 13(1).

29.

Ottman, R., et al., The other face of miR-17-92a cluster, exhibiting tumor suppressor
effects in prostate cancer. Oncotarget, 2016. 7(45): p. 73739-73753.

30.

Liu, H.P., et al., Epstein-Barr virus-encoded LMP1 interacts with FGD4 to activate
Cdc42 and thereby promote migration of nasopharyngeal carcinoma cells. PLoS Pathog,
2012. 8(5): p. e1002690.

31.

Kang, H.W., et al., miR-20a promotes migration and invasion by regulating TNKS2 in
human cervical cancer cells. FEBS Lett, 2012. 586(6): p. 897-904.

43

32.

Chang, C.C., et al., MicroRNA-17/20a functions to inhibit cell migration and can be used
a prognostic marker in oral squamous cell carcinoma. Oral Oncol, 2013. 49(9): p. 92331.

33.

Zins K., G.S., Lucas T., Abraham D., Aharinejad S., Targeting Cdc42 with the small
molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in
a preclinical mouse xenograft model by downregulation of PAK1 activity. Journal of
Translational Medicine, 2013.

44

